Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Dr Reddy’s Laboratories said its details plant in Andhra Pradesh got the Establishment Inspection Report (EIR) from the US sedate controller.
Dr Reddy’s Laboratories said that its Formulations Srikakulum Plant (SEZ) Unit I in Andhra Pradesh got the foundation review report (EIR) from US Food and Drug Administration (USFDA), demonstrating conclusion of the review. The examination characterization of this office is resolved as “No Action Indicated” (NAI). The declaration was made during market hours today, 13 May 2020.
On a merged premise, Dr Reddy’s Laboratories revealed an overal deficit of Rs 538.40 crore in Q3 December 2019 contrasted and a net benefit of Rs 500.30 crore in Q3 December 2018. Net deals rose 13.86% to Rs 4,383.80 crore in Q3 December 2019 over Q3 December 2018.
Dr Reddy’s Laboratories is occupied with giving drugs. The firm works in three portions: worldwide generics, pharmaceutical administrations and dynamic fixings (PSAI) and exclusive items.
Portions of the medication major were up 0.07% to Rs 3,774.75.
